Dr. Robert Popovian

The FDA needs to step up and fix the definition of strength. "Business as usual” under the existing language of the Biologics Price Competition and Innovation Act of 2009 means continued disincentives to promote a more aggressive uptake of biosimilars.
By any measure, today's announcement about the unexpected efficacy of the Pfizer/BioNTech coronavirus vaccine is great news. But, Pfizer's Dr. Robert Popovian cautions us that the job is not done. There are policies that are essential to ensure the vaccine is promoted to the public, distributed, and administered properly. And be priced so that everyone can get it. Devil. Details.